Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1669215

registered interest
date	10/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 13 September 2023 to Question 198352 on Dental Services: Cornwall, how funding recovered from NHS dentists may be spent by his Department.
tabling member constituency	St Ives
tabling member printed	Derek Thomas
uin	1380
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>NHS England has provided guidance for integrated care boards (ICBs) that requires dental funding to be ringfenced, with any unused resources re-directed to improve National Health Service dental access in the first instance. A schedule setting out the dental ringfence has been issued to ICBs. NHS England’s 2023/24 revenue finance and contracting guidance, which provides more detail, is available at the following link: https://www.england.nhs.uk/publication/2023-24-revenue-finance-and-contracting-guidance/</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 16/11/2023 12:10:42 answering member 4117 label Biography information for Andrea Leadsom previous answer version 1081 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
tabling member	4532 label Biography information for Derek Thomas

1669285

registered interest
date	10/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made a recent assessment of the potential merits of (a) accepting the recommendations of the report by the APPG on Brain Tumours entitled Pathway to A Cure, published on 28 February 2023, and (b) providing additional funding for multidisciplinary research into brain tumours.
tabling member constituency	Sheffield Central
tabling member printed	Paul Blomfield
uin	1339
answer	answer is ministerial correction date of answer 15/11/2023 answer text <p>The Department of Health and Social Care welcomes the All-Party Parliamentary Group report, recommendations of which continue to be worked through with the Department of Science, Innovation and Technology, and UK Research and Innovation and the Medical Research Council (MRC), and with the National Institute for Health and Care Research (NIHR).</p><p>The Tessa Jowell Brain Cancer Mission (TJBCM) recently announced two appointments to the inaugural Tessa Jowell Fellowship programme. These 12-month fellowships will support high quality training in neuro-oncology clinical practice and research, to ensure clinicians are equipped with the relevant research skills needed to lead neuro-oncology trials that change practice. Additionally, the TJBCM have designated 28 adult Tessa Jowell Centres of Excellence within the National Health Service, which has created a world-class network of brain tumour treatment and research centres to provide the best care and share best practice. These actions will help grow capacity for brain cancer research, attracting new researchers from multiple relevant disciplines and developing the community.</p><p>In May 2018, the Government announced £40 million for brain tumour research as part of the TJBCM through the NIHR. The £40 million funding will remain available; if we can spend more on the best quality science, we will do.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/11/2023 16:30:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4058 label Biography information for Paul Blomfield

1668830

registered interest
date	09/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the finding on page 4 of the report entitled Every minute counts, published by Parkinson's UK in September 2023, that 42% of patients with Parkinson's who are admitted to hospital get their medication on time every time.
tabling member constituency	Blackpool South
tabling member printed	Scott Benton
uin	1259
answer	answer is ministerial correction date of answer 15/11/2023 answer text <p>Within secondary care, hospital providers are responsible for ensuring that patients within hospital settings, including those with Parkinson’s disease, receive the appropriate medication on time.</p><p>NHS England has published a RightCare toolkit which aims to address challenges in providing services for those with progressive neurological conditions, including Parkinson’s disease. The toolkit provides advice on medicine optimisation, highlighting the importance of timely administration of specific drugs, such as Levodopa, in acute and community health settings.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/11/2023 16:41:02 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4793 label Biography information for Scott Benton

1669042

registered interest
date	09/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment has he made of the potential merits of utilising medicinal cannabis to treat children with intractable epilepsy.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	1238
answer	answer is ministerial correction date of answer 15/11/2023 answer text <p>The licensed cannabis-based medicine Epidyolex is prescribed and routinely funded by the National Health Service for the treatment of people aged two years old and over with Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. This follows approval by the Medicines and Healthcare products Regulatory Agency (MHRA) and assessment by the National Institute for Health and Care Excellence (NICE).</p><p>Clinical guidelines from NICE state that there is insufficient evidence of safety and efficacy to support a population-wide practice recommendation for the use of unlicensed cannabis-based products, for the treatment of adults and children with severe treatment-resistant epilepsy. NICE also made recommendations for further research to inform future commissioning decisions.</p><p>The Government encourages manufacturers to invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/11/2023 16:43:21 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4667 label Biography information for Mike Amesbury

1669062

registered interest
date	09/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surrogacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the report by the Law Commission entitled Building Families Through Surrogacy: A New Law, published on 29 March 2023; and whether it is his policy to reform surrogacy laws.
tabling member constituency	Richmond Park
tabling member printed	Sarah Olney
uin	1209
answer	answer is ministerial correction date of answer 14/11/2023 answer text <p>The Government is considering the reforms about surrogacy contained in the Law Commission report, Building Families Through Surrogacy, and will publish a Government response in due course. Ministers wrote to the Law Commission on 8 November 2023 to confirm that we would not be bringing forward legislation in this parliament.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 14/11/2023 10:10:39 answering member 4492 label Biography information for Maria Caulfield
tabling member	4591 label Biography information for Sarah Olney

1668298

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the continued NHS funding of modulator therapies that are used to treat (a) children, (b) new patients and (c) other patients with cystic fibrosis.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	710
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.</p><p>NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/11/2023 10:43:17 answering member 4423 label Biography information for Will Quince
tabling member	1409 label Biography information for Mr Gregory Campbell

1668388

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bipolar Disorder: Waiting Lists
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce waiting times for (a) diagnosis and (b) treatment of bipolar disorder.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	712
answer	answer is ministerial correction date of answer 15/11/2023 answer text <p>The NHS Long Term Plan commits to investing £2.3 billion extra funding a year in expanding and transforming mental health services by March 2024, enabling an extra two million people, including people with bipolar disorder, to be treated by mental health services within the National Health Service.</p><p>Through the NHS Long Term Plan, we are also expanding community mental health services. This includes new integrated community models for adults with severe mental illness including bipolar disorder. These new models are still in the early stages, and will take time to embed nationally, but will give at least 370,000 adults greater choice and control over their care and support them to live well in their communities by March 2024.</p><p>The Department also provided an additional £500 million in 2021/22 to accelerate our expansion plans and help address waiting times for mental health services. The NHS is also working towards implementing five new waiting time standards for people requiring mental healthcare in both accident and emergency and in the community, to ensure timely access to the most appropriate, high-quality support.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 15/11/2023 09:16:31 answering member 4492 label Biography information for Maria Caulfield
tabling member	1491 label Biography information for Kerry McCarthy

1668390

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Integrated Care Boards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which service specifications NHS England plans to (a) develop and (b) update before commissioning is delegated to integrated care boards.
tabling member constituency	Waveney
tabling member printed	Peter Aldous
uin	766
answer	answer is ministerial correction date of answer 16/11/2023 answer text <p>NHS England will only delegate specialised services to integrated care boards (ICBs) following a moderation process. This may mean that ICBs take on responsibility for commissioning specific specialised services at varying points in time. In parallel, NHS England is taking forward work to update service specifications for specialised services. Some specifications will need only minor changes and these will be progressed via a light touch process, whilst others require a deeper review which will take longer to complete.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 16/11/2023 12:42:17 answering member 4527 label Biography information for Helen Whately
tabling member	4069 label Biography information for Peter Aldous

1668437

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how the National Institute for Health and Care Research's Dementia Translational Research Collaborative plans to work with a Clinical Trial Acceleration Network for dementia to increase the UK’s share of clinical trials.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	799
answer	answer is ministerial correction date of answer 15/11/2023 answer text <p>The Dementia Translational Research Collaboration (D-TRC) is funded by the Department via the National Institute for Health &amp; Care Research. The D-TRC plays a critical role in coordinating dementia research in early phase clinical trials in the United Kingdom and seeks to offer a wider, more collaborative and cohesive network. The D-TRC's over-arching goal is the elevation of the UK as the world-leading place to conduct early phase clinical trials in dementia.</p><p>The Government will publish a full response to the Lord O’Shaughnessy independent review into commercial clinical trials in autumn 2023. The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the government made in May 2023 as well as all other recommendations in the review.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/11/2023 16:42:09 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4124 label Biography information for Chi Onwurah

1668464

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of setting the air quality target for PM2.5 at 10 micrograms per cubic meter by 2030 on (a) public health and (b) mortality rates.
tabling member constituency	Manchester, Gorton
tabling member printed	Afzal Khan
uin	911
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The UK Health Security Agency (UKHSA) does not currently intend to undertake any assessments of the impact of air quality targets for PM2.5 on public health or mortality rates.</p><p>In 2023, UKHSA estimated the impact of current emission policies on future mortality and hospital admissions in the United Kingdom. This found a greater than 30% reduction in attributable mortality beyond 2030 for current policies compared with 2018.</p><p>In 2018, the former Public Health England estimated that a one µg/m3 reduction in fine particulate air pollution in England could prevent around 50,000 cases of coronary heart disease, 15,000 strokes, 9,000 cases of asthma and 4,000 lung cancers between 2017 and 2025.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 13/11/2023 17:33:15 answering member 4492 label Biography information for Maria Caulfield
tabling member	4671 label Biography information for Afzal Khan